by NMS Group | Aug 3, 2022 | Uncategorized
NMS Group S.p.A, an oncology R&D powerhouse with a biotech discovering and developing innovative therapies for the treatment of cancer, a CRO and CDMO that together push Oncology Forward, has announced the appointment of Andrew Curtis as Chief Strategy Officer...
by NMS Group | Aug 1, 2022 | 2022
Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US...
by NMS Group | Jul 19, 2022 | News, News, News, News, News, News
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult...
by NMS Group | Jun 29, 2022 | 2022, 2022, 2022, 2022, 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021. “2021 was a challenging yet rewarding year for our Group. As we firmly believe in...
by NMS Group | Jun 28, 2022 | Uncategorized
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of...
by NMS Group | May 31, 2022 | Uncategorized
BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari:...
Welcome and Check out our new motion picture!
Recent Comments